Cross-Sector entity
Clarity Pharmaceuticals is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The clearest coverage concentration is manufacturing: 1 of 3 stories, with the rest divided among 2 other categories. Each carries 2 original sources on average.
3 verified stories tracked
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Clarity Pharmaceuticals is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. The clearest coverage concentration is manufacturing: 1 of 3 stories, with the rest divided among 2 other categories. Each carries 2 original sources on average. We currently track 3 Cross-Sector stories that mention Theragenics, all published on March 25, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Theragenics. Shared-story counts are live from our verified record — not editorial picks.
Phase III Milestones
Anticipated data readouts for TCT imaging agents supported by Cu-64 supply.
Supply Chain Integration
Integration of Theragenics' output into Clarity's clinical trial logistics.
Production Ramp-up
Expected commencement of large-scale isotope production for late-stage clinical trials.
Process Integration
Technical teams begin integrating manufacturing protocols and quality control standards.
Agreement Signed
Clarity and Theragenics formalize the large-scale manufacturing supply deal for Cu-64.
Clarity Pharmaceuticals has signed a major manufacturing supply agreement with Theragenics to secure large-scale production of copper-64. This partnership bolsters the supply chain for Clarity’s Targeted Copper Theranostics platform as it moves toward late-stage clinical trials.
Clarity Pharmaceuticals has entered into a multi-year manufacturing supply agreement with Theragenics for the production of copper-64 (Cu-64). This partnership secures a reliable, large-scale supply of the isotope to support Clarity's clinical trials and future commercialization of its Targeted Copper Theranostics platform.
Clarity Pharmaceuticals has secured a large-scale manufacturing supply agreement with Theragenics for the production of copper-64. This strategic partnership addresses critical supply chain bottlenecks for radiopharmaceuticals, ensuring a reliable flow of isotopes for Clarity’s diagnostic and therapeutic clinical trials.
Source: vietnamtribune.com · malaysiasun.com
